^ Klein C, Karanges E, Spiro A, Wong A, Spencer J, Huynh T, Gunasekaran N, Karl T, Long LE, Huang XF, Liu K, Arnold JC, McGregor IS (November 2011). "Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats". Psychopharmacology. 218 (2): 443–457. doi:10.1007/s00213-011-2342-0. PMID 21667074.
Cannabidiol (CBD), a non-psychoactive segment of the marijuana plant, has created huge enthusiasm among researchers and physicians.  CBD Oil applies its remedial effect on an atomic level is as yet being sorted out. Cannabidiol is a pleiotropic sedate in that it produces numerous impacts through various atomic pathways. CBD Oil acts through different receptor-free channels and by official with various non-cannabinoid receptors and particle channels.
Hi, I had ovarian cancer stage 2 and went to do chemotherapy for 16 times in 2014. It came back last year 2016 but I did not do chemotherapy or radiation therapy as suggested by the doctor. I am taking hormone therapy at the moment. I would like to use cannabis oil but which one and how much CBD and how much THC should I take for ovarian cancer? Can anyone give some idea?. Thank you very much.
Nabiximols (brand name Sativex) is a patented medicine containing CBD and THC in equal proportions. The drug was approved by Health Canada in 2005 for prescription to treat central neuropathic pain in multiple sclerosis, and in 2007 for cancer related pain.[39][40] In New Zealand Sativex® is approved for use as an add-on treatment for symptom improvement in patients with moderate to severe spasticity due to Multiple Sclerosis who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.[41]

Some individuals have been found to have mutations on the CNR1 gene, which is responsible for coding the CB1 receptor (a type of receptor in cells throughout your body that interacts with cannabinoids). Issues with the CNR1 gene can ultimately result in a poorly functioning endocannabinoid system, which is an important variable when figuring out how to use CBD oil.
CBD oil may be of some benefit to those with addiction, suggests a review published in the journal Substance Abuse in 2015. In their analysis of 14 previously published studies, scientists determined that CBD may have therapeutic effects in people with opioid, cocaine, and/or psychostimulant addiction. They also found that CBD may be beneficial in the treatment of cannabis and tobacco addiction. There is some evidence that CBD may block or reduce the effects of THC on the mind.
In the USA the legal definition of “industrial hemp,” per Section 7606 of the Agricultural Appropriations Act of 2014, is “INDUSTRIAL HEMP — The term ‘‘industrial hemp’’ means the plant Cannabis sativa L. and any part of such plant, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis.”

I ordered this a few weeks ago after we got scammed by another CBD product company. My husband was very leary of trying another product. But today he had left for work ( he transports cars to auction) and came back due to I forgot my drops. He is also mad that I havent placed an order yet and we are almost out. So order is going in for two bottles ASAP for the 1000 mg. This product is well worth the money
...with due respect, your experience Locsta is almost precisely what happened with my....chihuahua. Degenerative disc disease, excruciating pain, prednisone worked, but couldn't keep her on it..pain killers and muscle relaxants didn't help, really thought I would have to put her down. Chi bloggers suggested CBD; gave PetReleaf a shot--like you, literally within minutes I could see the difference, in days she was pain free and now is back in charge of our world. The real key here is that with my dog, there is zero, nada, chance that there was any placebo effect...
^ Jump up to: a b c d Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS (December 2012). "Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences (Review). 367 (1607): 3364–78. doi:10.1098/rstb.2011.0389. PMC 3481531. PMID 23108553.

Zuardi, A. W., Crippa, J. A., Hallak, J. E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., … & Guimarães, F. S. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Abstract]. Current Pharmaceutical Design, 18(32), 5,131–5,140. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22716160
×